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ABSTRACT
Introduction: Cardiovascular disease and dementia
share a number of risk factors including hypertension,
hypercholesterolaemia, smoking, obesity, diabetes and
physical inactivity. The rise of eHealth has led to
increasing opportunities for large-scale delivery of
prevention programmes encouraging self-management.
The aim of this study is to investigate whether a
multidomain intervention to optimise self-management
of cardiovascular risk factors in older individuals,
delivered through an coach-supported interactive
internet platform, can improve the cardiovascular risk
profile and reduce the risk of cardiovascular disease
and cognitive decline.
Methods and analysis: HATICE is a multinational,
multicentre, prospective, randomised, open-label
blinded end point (PROBE) trial with 18 months
intervention. Recruitment of 2600 older people
(≥65 years) at increased risk of cardiovascular disease
will take place in the Netherlands, Finland and France.
Participants randomised to the intervention condition
will have access to an interactive internet platform,
stimulating self-management of vascular risk factors,
with remote support by a coach. Participants in the
control group will have access to a static internet
platform with basic health information.
The primary outcome is a composite score based on
the average z-score of the difference between baseline
and 18 months follow-up values of systolic blood
pressure, low-density-lipoprotein and body mass index.
Main secondary outcomes include the effect on the
individual components of the primary outcome, the
effect on lifestyle-related risk factors, incident
cardiovascular disease, mortality, cognitive functioning,
mood and cost-effectiveness.
Ethics and dissemination: The study was approved
by the medical ethics committee of the Academic
Medical Center in Amsterdam, the Comité de
Protection des Personnes Sud Ouest et Outre Mer in
France and the Northern Savo Hospital District
Research Ethics Committee in Finland.
We expect that data from this study will result in a
manuscript published in a peer-reviewed clinical open
access journal.
Trial registration number: ISRCTN48151589.
BACKGROUND
Despite impressive reductions of its inci-
dence in many countries, cardiovascular dis-
eases (CVD) continue to be a major public
health issue with over 4 million deaths in
Europe each year.1 In parallel, the global
prevalence of dementia is likely to increase
in the coming years, mainly due to increased
life expectancy.2 CVD and dementia share a
number of risk factors including hyperten-
sion, hypercholesterolaemia, smoking, dia-
betes, obesity and physical inactivity.3 4
Treatments targeting most of these risk
factors are effective for the prevention of
CVD.5–7 Even small improvements of vascular
risk factor management in a large
Strengths and limitations of this study
▪ The study proposes the assessment of a
pragmatic, easily implementable, coach-
supported interactive internet platform for the
improvement of the cardiovascular risk profile.
▪ The strengths of the study include the large
sample size, the multinational recruitment and
cooperation and the relatively less investigated
older target population.
▪ Limitations include the relatively short follow-up.
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population, can lead to a large effect on incident cardio-
vascular disease at the population level8 and substantial
reductions in healthcare costs.9
Although up to 30% of dementia cases are attributable
to modiﬁable (mostly cardiovascular) risk factors,10
there is currently insufﬁcient evidence from randomised
controlled trials (RCTs) that treatment will also reduce
dementia incidence. Vascular risk factors rarely occur in
isolation. It is plausible that targeting multiple risk
factors simultaneously can have an additive effect on the
reduction of the risk of CVD and dementia, but RCTs
targeting the older population are rare and with mixed
results.11–13 However, the recently published large RCT
‘Finnish Geriatric Intervention Study to Prevent
Cognitive Impairment and Disability (FINGER)’, suggest
that a multidomain lifestyle intervention could improve
or maintain cognitive functioning in at-risk elderly
people from the general population.14
In spite of clear guidelines for cardiovascular risk man-
agement mainly for younger adults,15 but also applied on
older adults, the sobering reality of daily practice is that
target values are often not reached,16 17 leaving room for
a substantial improvement. Both patient and doctor
factors play a role in this gap between evidence and prac-
tice.18 Innovative strategies to improve cardiovascular risk
management are therefore urgently needed.
Patient self-management is a potentially powerful strat-
egy to improve adherence to therapy in CVD risk reduc-
tion.19 20 Speciﬁc patient characteristics can determine
the strategies applied at the individual level. Increasing
knowledge about a healthy lifestyle and the possibility
for tailor-made prevention programmes can empower
individuals and improve adherence with pharmaco-
logical and non-pharmacological interventions.21
When designing a trial on prevention of cardiovascu-
lar disease and dementia, the optimal age-range of the
target population is matter of debate. The beneﬁts of
higher efﬁcacy in midlife are counteracted by the large
sample size and long follow-up required to detect an
effect on incident disease.22 The optimal time-window
depends on the peak incidence age, and is probably
somewhere in late midlife or early late-life.23
The internet has become a major source of informa-
tion for people of all ages, and its use among older
people throughout Europe has increased dramatically,
making it a potentially suitable medium for the delivery
of widely implementable healthcare interventions.24
Together with the rise of eHealth this creates opportun-
ities for large-scale delivery of prevention programmes
encouraging self-management.25
In the Healthy Ageing Through Internet Counselling
in the Elderly (HATICE) trial we investigate whether a
coach-supported interactive internet intervention to
optimise self-management of cardiovascular risk factors
in older individuals can improve the cardiovascular risk
proﬁle and reduce the risk of cardiovascular disease and
cognitive decline.
METHODS
Study design
HATICE is a pragmatic, multinational, multicentre,
investigator initiated, prospective, randomised, open-
label blinded end point (PROBE),26 trial with
18 months intervention and follow-up. Owing to the
nature of the intervention, complete double blinding is
not possible. Investigators evaluating outcome measures
are blinded for the randomisation group and the
primary outcome is based on objective parameters.
Study population and recruitment
The study population will consist of community-dwelling
people aged 65 years or older who have two or more car-
diovascular risk factors and/or manifest cardiovascular
disease or diabetes mellitus. This leads to a mixed popu-
lation with an indication for either primary or secondary
prevention. Inclusion and exclusion criteria are listed in
table 1.
Recruitment takes place in the Netherlands, Finland
and France. Based on a pilot study (later described) and
experience from previous trials14 27 28 we expect a
response rate of ∼10%. In the Netherlands recruitment
will take place through registration lists of all individuals
≥65 years registered in primary care practices. In
Finland recruitment will take place by inviting indivi-
duals from the population registry based on age, by
selecting participants from previous population-based
surveys, as was previously carried out to recruit for
RCTs,29 and by advertisements in local media, patient
organisations and their websites and healthcare centres.
In France participants will be enrolled from various
sources. In addition to recruitment through general
practitioners (GP), prevention centres, cardiovascular
risk factors consultations and the geriatrics department
and memory clinics in the Toulouse area, participants
will also be recruited through mailing lists and advertise-
ments in local media, seniors clubs and conferences.
People aged ≥65 years will receive an information
letter and are invited to apply through a country speciﬁc
website or emailing or calling the local study centre.
Those interested will receive a prescreening telephone
call. If eligible, people are invited to attend the ﬁrst
screening visit.
Recruitment started in March 2015.
Intervention
Participants randomised to the intervention condition
will have access to an interactive internet platform, spe-
ciﬁcally designed for use by older people (ﬁgure 1).
The platform is in the participants own language
(Finnish, French or Dutch) and facilitates self-
management of vascular and lifestyle-related risk factors,
including blood pressure, overweight, physical inactivity,
diet, smoking, diabetes and hypercholesterolaemia.
After secure login, a participant can view his/her own
cardiovascular risk proﬁle created through baseline
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measurements. At the interactive part of the platform,
the participants can set a personal goal for lifestyle
change, make a corresponding action plan, monitor
goals by entering data (eg, blood pressure or a food
diary), join lifestyle activity groups and correspond with
their coach, whom they have met in person at the base-
line assessment. In addition, participants can ﬁnd health
information in static and interactive education-modules,
watch peer videos on lifestyle change, and use a pro-
gramme for cognitive training.
The platform and the guidance provided by the coach
are based on current European and national guidelines
for cardiovascular risk management.15 When indicated,
this is adapted to national guidelines from one of the
three countries where participants are recruited. Owing
to the heterogeneous population in this trial, which
includes participants with elevated cardiovascular risk
with or without established CVD, primary as well as sec-
ondary prevention guidelines will be applied. The
HATICE intervention platform does not replace existing
healthcare in any way, but is offered as an add-on.
The platform is supported by a coach trained in motiv-
ational interviewing. All coaches in all three countries
work according to a coach protocol set up by the
research team. Guided by the preferences of the partici-
pant, the coach provides remote support by assisting in
realistic goal-setting according to the ‘speciﬁc, measur-
able, attainable, realistic and time bound (SMART) prin-
ciple.30 Communication between the participant and the
coach is through a messaging system within the
platform. The coach receives automatic alerts when par-
ticipants enter measurements or when a participant has
not been active on the platform for more than 3 weeks.
The coach advises the participant to log in at least once
a week, but this is not compulsory.
There are regular national and international meetings
with the coaches and the research team to discuss the
intervention and to solve discrepancies between coun-
tries and coaches.
Participants randomised to the control condition will
have access to an internet platform with only the static
information on cardiovascular risk factors, but lacking
interactive features and the support of a coach.
Pilot
Between September 2014 and February 2015 a pilot
study was conducted in the three participating countries
with a total of 41 participants, in order to test the trial
procedure and the platform. We adjusted the protocol
and the platform where needed, according to the feed-
back of the end users; for example, enlargement of
electronic buttons, more guidance on the use of the
platform (eg, introduction video and more instructions
from the coach) and more positive tone of voice
(eg, ‘health factor’ instead of ‘risk factor’).
Primary outcome
The primary outcome is a composite score based on the
average z-score of the difference between baseline and
18 months follow-up values of systolic blood pressure,
Table 1 Overview of inclusion and exclusion criteria
Inclusion criteria Exclusion criteria
▸ Age ≥65 years
▸ Available informant
▸ ≥2 Cardiovascular risk factors defined as:
– Hypertension, defined by any of the following:
○ Diagnosis by specialist or GP
○ Currently on antihypertensive drugs
○ Baseline BP: if <80 years; ≥140/90 mm Hg; If ≥80 years: systolic
BP ≥160 mm Hg
– Dyslipidaemia, defined by any of the following:
○ Diagnosis by specialist or GP
○ Currently on lipid-lowering drugs
○ Total cholesterol ≥5.0 mmol/L and/or LDL ≥2.5 mmol/L
– Overweight, defined by any of the following:
○ BMI ≥30 kg/m2
○ Waist circumference men ≥102 cm, women ≥88 cm
– Active smoking
– Lack of physical exercise defined as below the WHO norm of 30 min of
intermediate exercise, 5 times a week
AND/OR
▸ History of cardiovascular disease: stroke/transient ischaemic attack,
myocardial infarction, angina pectoris and/or peripheral arterial disease.
(diagnosis by specialist or GP)
▸ Diabetes mellitus (diagnosis by specialist or GP)
▸ Previously diagnosed dementia
▸ MMSE score <24
▸ Any condition expected to limit
18 months compliance and follow-up
▸ Computer illiteracy, defined as unable to
send an email
▸ Severe (visual) impairment interfering
with operating a computer
BMI, body mass index; BP, blood pressure; GP, general practitioner; LDL, low-density-lipoprotein; MMSE, Mini-Mental State Examination.
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low-density-lipoprotein (LDL) and body mass index
(BMI). Several considerations have led to the decision for
this outcome. First, a multidomain outcome capturing
the potential effect of our multidomain intervention on
a composite of risk factors was deemed appropriate.
Second, no existing cardiovascular risk score can be
applied to both primary and secondary prevention,
whereas our pragmatic trial targets a mixed population
with an indication for primary or secondary prevention.
Third, we deemed it inappropriate to include any param-
eter based on patient-reported measures (eg, physical
activity questionnaire) in our primary outcome due to
the risk of reporting bias; self-reported parameters
were considered insufﬁciently reliable for the primary
outcome.
Secondary outcomes
Main secondary outcomes include the difference
between baseline and month 18 on the individual com-
ponents of the primary outcome, the difference in
lifestyle-related risk factors (physical exercise, diet,
smoking status), the difference in estimated 10-year car-
diovascular disease risk based on the Framingham car-
diovascular disease risk score (measured at 18 months),
cardiovascular risk factors, aging and dementia risk-
score(CAIDE),31 incident cardiovascular disease, mortal-
ity, disability, cognitive functioning, incident dementia,
physical ﬁtness, mood and cost-effectiveness. The clinical
outcomes stroke, myocardial infarction, angina pectoris,
peripheral arterial disease, dementia and death will be
adjudicated by an independent outcome committee in
each country.
Study logistics
The overall study logistics are shown in ﬁgure 2. In this
trial, each participant will make three visits to the study
centre. After the prescreening by telephone, the ﬁrst
(screening) visit will take place. Informed consent will
be signed by every participant. Eligibility criteria will be
checked by recording blood pressure, weight, height,
hip and waist circumference, cognition (Mini-Mental
State Examination32) and medical history. Blood pres-
sure will be measured twice with an Omron M6 Comfort
(HEM-7321-E) device in resting sitting position. After
this visit the participants are requested to ﬁll in seven
online self-assessment questionnaires at home:
Community Healthy Activities Model Program for
Seniors physical activity questionnaire,33 a nutrition
questionnaire (adapted from ePredice34), 15-item
Geriatric Depression Scale (GDS),35 Late Life Function
and Disability Instrument (only disability part),36
EuroQol EQ5D-3L,37 Hospital Anxiety and Depression
Scale (only anxiety part)38 and the Partners in Health
scale39 (participant rated self-management measure).
Validated versions of these questionnaires in the local
languages (Finnish, French, Dutch) will be used, when-
ever available. If not, the validated English version of the
questionnaire was translated according to the proper
translation guideline40 into the three languages.
Figure 1 Screenshot of intervention portal (simulated values, participant and coach).
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Before the baseline visit, a fasting blood sample will be
drawn for determining blood glucose, glycated haemo-
globin, cholesterol spectrum, C-reactive protein and
DNA storage. DNA will be stored locally, but is consid-
ered as one biobank. During the second (baseline) visit,
which will take place ∼2 weeks after the screening visit,
all outcome assessment instruments will be applied.
Physical functioning will be assessed using the short
physical performance battery.41 Medication use and
results of blood tests will be recorded. Cognitive func-
tion in different domains will be tested using the Stroop
test,42 auditory verbal learning test43 44 and semantic
verbal ﬂuency test (animal naming). For the interven-
tion group this visit will be concluded with a motiv-
ational interview by the coach and an explanation of the
platform to facilitate its use.
At 12 months, the participants are requested to ﬁll in
all seven online self-assessment questionnaires again and
will receive a telephone evaluation call. Participants
from both groups will be called and medication lists will
be checked. The participants from the intervention
group will have an additional interview with a strong
focus on their motivation with their own coach.
At the end of study visit at 18 months all parameters
assessed during screening and baseline visits and the
online questionnaires are recorded again by an inde-
pendent assessor, blinded to treatment allocation.
The electronic case report forms are built into the
platform and only available for the assessors and
researchers. All data will be coded, to assure conﬁden-
tially. Data will be managed in one central server for all
three countries.
Randomisation and blinding
Participants are randomised during the baseline visit
in a 1:1 ratio using central randomisation according to
a computer-generated randomisation sequence. We
decided not to stratify for any characteristic, since the
magnitude of the sample size, even within one
country, renders any imbalance between the groups
extremely unlikely.45 46 In case of spouse/partner par-
ticipation, partners will be allocated to the same treat-
ment arm to prevent contamination. It is explained to
participants that they are randomised to one of two
internet-platforms to improve lifestyle, without further
details.
Figure 2 Study logistics.
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The coaches who support the participants in the inter-
vention group are not blinded. Outcome assessment at
the end of study at month 18 will be carried out by an
independent assessor blinded to treatment allocation.
Safety
The intervention is considered low-risk, since no drugs
are prescribed and only lifestyle advice and support is
provided. Serious adverse events (AE) resulting from the
intervention are not expected. No data safety and moni-
toring board is installed. AEs are however monitored
using a 3-monthly questionnaire to be ﬁlled in online by
the participant in both treatment arms. If the partici-
pant is not able to ﬁll in the questionnaire due to a
medical condition, the informant will be contacted to
ﬁll in the questionnaire. This questionnaire is automatic-
ally generated and concerns new cardiovascular events
(myocardial infarction, stroke, transient ischaemic
attack, angina pectoris, peripheral arterial disease, dia-
betes mellitus), GP visits and institutionalisation. A logis-
tic algorithm was designed to optimise data collection
on AEs and end point during the study (ﬁgure 3) and
minimise missing data on outcomes.
STATISTICAL ANALYSES
Sample size
We originally based our power calculation on proportions.
With advancing insight we decided on a continuous
primary outcome, resulting in a new sample size calcula-
tion, again taking into account the effect of participants
randomised as couples. We base the new sample size cal-
culation on the effect-sizes of the HATICE primary
outcome as observed in the preDIVA and FINGER
trials.14 27 In the PreDIVA study the mean difference in z-
score of the HATICE primary outcome between baseline
and two year follow-up is 0.070 (p=0.002; intervention
group −0.194 and control group −0.124). In the FINGER
study this mean difference is 0.041 (p=0.11; intervention
group −0.128 and control group −0.087). To avoid the
risk of being underpowered since the effect was non-
signiﬁcant in the FINGER study, we base our sample size
calculation on an effect size of 0.06.
Based on the ﬁrst 1000 recruitments, we estimate that
17.5% of the participants will be recruited as a couple.
Couples can be considered the smallest possible clusters
(n=2). Although intra-cluster correlation coefﬁcients
(ICC) in RCTs are typically below 0.05, the ICC for vas-
cular and lifestyle-related risk factors within small clus-
ters of relatives may be much higher, up to 0.25.47
With 80% power, a 0.05 two-sided signiﬁcance level,
accounting for an estimated 14% attrition based on previ-
ous experiences in our own multi-domain prevention
study,14 an ICC of 0.2547 and an effect size of 0.06 the
required sample size is estimated to be 2534 participants in
total. To allow for unexpected factors we raise this to 2600.
Because the meaning of a difference in z-scores is dif-
ﬁcult to interpret, we estimated the threshold for a
Figure 3 Periodic end point and adverse events check questionnaire during trial. AE, adverse event; AEQ, adverse event/end
point questionnaire; C, coach or research assistant; CVD, cardiovascular disease; P, participant.
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clinically relevant difference in z-score by using the
follow-up data in preDIVA for clinical outcomes. For this
purpose we compared preDIVA participants who did
develop CVD or dementia with those who didn’t during
an average follow-up of 6.7 years. In preDIVA the
change in z-score after 2 years was −0.205 in participants
who developed CVD or dementia and −0.146 in partici-
pants who did not develop CVD or dementia. We there-
fore assume that a difference of 0.059 on the composite
primary outcome of HATICE can be considered as
clinically relevant.
Data analysis
For the primary analyses we will use a univariate general
linear model to assess the effect on the primary
outcome. All analyses will be according to the
intention-to-treat principle. No imputation of the
primary outcome will be made for the primary analysis.
If there are signiﬁcant differences in baseline character-
istics, these will be adjusted for in secondary analyses.
We will evaluate country, centre and coach differences
and if indicated, this will also be adjusted for in second-
ary analyses.
The effect on the individual variables of the composite
outcome (ie, blood pressure, BMI, LDL) and on the
10-year cardiovascular disease risk calculated using the
Framingham risk score will be analysed using general
linear models. Since the Framingham risk score is
heavily inﬂuenced by age, the calculation of the risk
score after 18 months will be carried out using the base-
line age, in order to prevent obscuration of a true treat-
ment effect by increasing age. For clinical dichotomous
secondary outcomes, including incident cardiovascular
disease and mortality, standard Cox-proportional hazards
models will be used.
Self-assessment scales, which are mostly ordinal, will
be analysed as linear scales where possible. If a self-
assessment instrument has a deﬁned cut-off for the pres-
ence or absence of a condition, (eg, the GDS) χ2 statistics
will be used.
The full statistical analysis plan will be produced prior
to the data analysis.
Economic evaluation
The economic evaluation of this trial will be performed
as a cost-effective analysis (CEA) with the costs per
patient with a reduced risk of CVD and cognitive
decline as outcome parameter. Additionally, a cost-utility
analysis (CUA) will be performed with the costs per
quality adjusted life year (QALY) as outcome parameter.
A healthcare perspective will be taken with a compara-
tive assessment of the most relevant medical costs. These
include the costs of hospital visits, emergency room
visits, visits to the GP or a physician and institutionalisa-
tion for the two study groups. We will take the additional
costs associated with implementing this intervention into
account. Owing to the inclusion criteria for age, the vast
majority of participants will be retired and therefore
costs of loss of productivity are not taken into account.
Unit costing will be based on national guidelines for
costing in healthcare research.
The EQ-5D-3L will be used to generate health status
scoring proﬁles over time and this will be transposed
into QALY’s. Incremental cost-effectiveness analyses will
be performed to estimate the extra costs per additional
patient with a reduced risk of CVD and cognitive decline
as well as the extra costs per QALY. Country-speciﬁc sub-
group analyses will be performed to account for differ-
ences in healthcare delivery.
Depending on the outcomes of the CEA and CUA it
will be assessed whether a modelling scenario of internet
counselling with a lifetime horizon is opportune and if
so, how it should be elaborated.
The opportunity arises if the intervention proves
effective, the health states at the end of the 18 months
of follow-up differ between the groups and such differ-
ence in health states is expected to have an impact on
need for healthcare for the remainder of their lifetime.
If so, the groups will continue to differ by their costs of
healthcare and the costs per QALY may shift for the
better. If the 18 months costs per QALY are already
acceptable against existing standards of societal willing-
ness to pay per QALY at the time of analysis and further
improvement is expected, then no modelling scenario is
needed to underpin reimbursement decisions. If the
costs per QALY are unacceptable despite proven effect-
iveness, then modelling is needed to ﬁnd out the impact
of the lifetime perspective on the cost-effectiveness
acceptability of the lifestyle internet platform. Modelling
of costs and QALYs from a lifetime perspective combines
study and literature data on costs and QALYs in different
stages of cardiovascular disease and/or cognitive impair-
ment on the one hand with literature data on risks
(hazard rates) of disease progression. If modelling
seems opportune, then the current study will include
the design for a subsequent modelling study.
DISCUSSION
In HATICE, we will study the effect of an internet inter-
vention to improve lifestyle-related risk factors for CVD,
with the aim to improve the whole cardiovascular risk
proﬁle and preventing cardiovascular mortality and mor-
bidity, including cognitive decline. The wide and still
growing access and use of the internet offers an excellent
possibility to deliver an eHealth intervention in a scalable
and cost-effective way. By focusing on the perspective of
older people during the development phase, we have built
an intuitive, easy to use platform, allowing for widespread
use among older adults with only limited computer skills.
The pilot of this study showed that the platform was easy
to use and appreciated by the participants.
Improvement in physical activity can already be reached
by regular walking, exercise groups and brief exercise
advice by mail in a cost-effective way.50 A Cochrane
meta-analysis showed that interactive computer-based
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interventions are effective for weight loss and weight main-
tenance.51 Also, support and self-management in changing
lifestyle leads to improved health outcomes,47 52 and a
stronger long-term effect.53 Using an innovative interactive
approach based on the stimulation of self-management
with coach support in HATICE can potentially lead to scal-
able and cost-effective methods to contribute to healthy
ageing and the prevention of cardiovascular disease and
cognitive decline.
The choice of primary outcome was carefully made. A
clinically relevant outcome parameter, such as incident
cardiovascular disease or dementia, would have required
a longer follow-up or a signiﬁcantly larger sample size,
both not deemed feasible. As such HATICE can be con-
sidered a large proof-of principle trial.
HATICE is a pragmatic trial, targeting a mixed popula-
tion and delivering primary and secondary prevention.
This precludes the use of one of the established cardio-
vascular risk scores (eg, Framingham,54 SCORE,55 which
are validated for either primary or secondary preven-
tion) as a primary outcome. Despite its limitations, a
combined z-score of measurable risk factors is in our
opinion the best reﬂection of an effect on the cardiovas-
cular risk proﬁle in a heterogeneous population with dif-
ferent risk factors present at baseline.
The different source populations will result in differ-
ences in characteristics of participants from the three
countries. This resulting heterogeneity increases exter-
nal validity of the results to a wider population and will
allow for secondary analyses on the effect of the inter-
vention in different populations.
The effects of the intervention can be quite differ-
ent in each of the participating countries, since the
implementation of cardiovascular risk management in
these three countries is organised differently. The
extensive experience of the research team in the dif-
ferent participating countries with large randomised
prevention trials (FINGER,14 MAPT28 and PreDIVA27)
in older populations facilitates the execution of this
large RCT.
Although many older people use the internet now-
adays, those who feel conﬁdent enough to participate in
an eHealth trial might be higher educated. This will
inﬂuence the generalisability and will have to be taken
into account when interpreting the results particularly
when assessing effect on cognition.
In our primary outcome we have included BMI.
Although this may not be the best anthropometric par-
ameter to reﬂect the risk of cardiovascular disease asso-
ciated with obesity, it is the least subject to bias during
assessment (as opposed to waist circumference or waist-
hip ratio).
In spite of the blinded outcome assessment at the
ﬁnal follow-up visit, a certain degree of unblinding due
to participant’s expression of experiences with the plat-
form might occur.
The pragmatic design of the intervention, independ-
ent of existing healthcare structures, will facilitate easy
and wide implementation throughout Europe, if proven
effective. The tailor-made character of the intervention
speciﬁcally suited to the needs of older individuals ﬁts
with the current development towards a more persona-
lised approach in medicine.
Ethical approval and dissemination
Results from this study will be published in a peer-
reviewed journal electronically and in print.
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